Zhejiang Jiuzhou Pharmaceutical Toekomstige groei

Future criteriumcontroles 2/6

Zhejiang Jiuzhou Pharmaceutical zal naar verwachting groeien in winst en omzet met respectievelijk 20.2% en 12% per jaar. De winst per aandeel zal naar verwachting groeien met 20.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 11.9% zijn.

Belangrijke informatie

20.2%

Groei van de winst

20.3%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	18.2%
Inkomstengroei	12.0%
Toekomstig rendement op eigen vermogen	11.9%
Dekking van analisten	Low
Laatst bijgewerkt	22 Nov 2024

Recente toekomstige groei-updates

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Apr 11

Recent updates

Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Shares Leap 25% Yet They're Still Not Telling The Full Story

Oct 01

Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Seems To Use Debt Quite Sensibly

Sep 25

Here's Why Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Can Manage Its Debt Responsibly

Jun 13

Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Business And Shares Still Trailing The Market

May 24

Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Solid Earnings May Rest On Weak Foundations

May 01

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Apr 11

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Feb 28

Winst- en omzetgroeiprognoses

SHSE:603456 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	6,618	1,245	N/A	1,619	4
12/31/2025	6,370	1,189	N/A	1,491	5
12/31/2024	5,644	1,024	N/A	1,590	5
9/30/2024	4,912	697	-192	869	N/A
6/30/2024	5,033	886	-43	961	N/A
3/31/2024	5,248	989	-185	767	N/A
12/31/2023	5,523	1,033	431	1,360	N/A
9/30/2023	5,649	1,145	311	1,135	N/A
6/30/2023	5,745	1,075	524	1,386	N/A
3/31/2023	5,823	994	518	1,300	N/A
12/31/2022	5,445	921	512	1,226	N/A
9/30/2022	5,432	904	787	1,490	N/A
6/30/2022	5,150	827	450	1,098	N/A
3/31/2022	4,581	747	448	1,050	N/A
12/31/2021	4,063	634	98	678	N/A
9/30/2021	3,906	614	-71	456	N/A
6/30/2021	3,507	526	115	494	N/A
3/31/2021	3,112	443	-59	330	N/A
12/31/2020	2,647	381	85	400	N/A
9/30/2020	2,404	341	308	612	N/A
6/30/2020	2,167	265	11	357	N/A
3/31/2020	2,010	227	206	529	N/A
12/31/2019	2,017	238	234	554	N/A
9/30/2019	1,952	198	43	357	N/A
6/30/2019	1,800	171	127	406	N/A
3/31/2019	1,785	149	114	363	N/A
12/31/2018	1,862	157	34	265	N/A
9/30/2018	1,752	128	186	325	N/A
6/30/2018	1,839	163	N/A	282	N/A
3/31/2018	1,798	157	N/A	215	N/A
12/31/2017	1,717	148	N/A	275	N/A
9/30/2017	1,696	139	N/A	157	N/A
6/30/2017	1,694	147	N/A	177	N/A
3/31/2017	1,697	116	N/A	85	N/A
12/31/2016	1,653	111	N/A	137	N/A
9/30/2016	1,559	118	N/A	83	N/A
6/30/2016	1,500	126	N/A	44	N/A
3/31/2016	1,458	197	N/A	73	N/A
12/31/2015	1,445	200	N/A	141	N/A
9/30/2015	1,432	195	N/A	110	N/A
6/30/2015	1,349	170	N/A	98	N/A
3/31/2015	1,325	142	N/A	184	N/A
12/31/2014	1,286	133	N/A	10	N/A
9/30/2014	1,229	155	N/A	138	N/A
12/31/2013	1,310	166	N/A	204	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 603456 ( 20.2% per jaar) ligt boven de spaarquote ( 2.8% ).

Winst versus markt: De winst van 603456 ( 20.2% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 26.3% per jaar).

Hoge groeiwinsten: De winst van 603456 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 603456 ( 12% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 13.9% per jaar).

Hoge groei-inkomsten: De omzet van 603456 ( 12% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 603456 zal naar verwachting over 3 jaar laag zijn ( 11.9 %).

Zhejiang Jiuzhou Pharmaceutical Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 13% to CN¥20.15

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Price target decreased by 13% to CN¥32.14

Price target decreased to CN¥50.46

Price target decreased to CN¥63.18

Price target increased to CN¥69.15

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.39 in 3Q 2023)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Shares Leap 25% Yet They're Still Not Telling The Full Story

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 17%

Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Seems To Use Debt Quite Sensibly

Frontage Laboratories (Shanghai) Co. Ltd. agreed to acquire remaining 25% stake in Frontage Laboratories (Suzhou) Co.,Ltd. from Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) for CNY 19.6 million.

Second quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.38 in 2Q 2023)

Price target decreased by 13% to CN¥20.15

Dividend of CN¥0.50 announced

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2024 Results on Aug 27, 2024

Here's Why Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Can Manage Its Debt Responsibly

Now 22% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Business And Shares Still Trailing The Market

Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Solid Earnings May Rest On Weak Foundations

First quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.32 in 1Q 2023)

Now 21% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Price target decreased by 13% to CN¥32.14

Now 20% undervalued after recent price drop

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Annual General Meeting, May 16, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q1, 2024 Results on Apr 25, 2024

Now 24% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Investor sentiment improves as stock rises 17%

Now 23% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Fiscal Year 2023 Results on Apr 09, 2024

Third quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.34 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.31 in 2Q 2022)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.25 in 1Q 2022)

Now 21% undervalued after recent price drop

Price target decreased to CN¥50.46

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.24 in 3Q 2021)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) announces an Equity Buyback for CNY 100 million worth of its shares.

Zhejiang Jiuzhou Pharmaceutical Co., Ltd announced that it expects to receive CNY 2.5 billion in funding

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.22 in 2Q 2021)

Price target decreased to CN¥63.18

Less than half of directors are independent

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) signed Investment Agreement to acquire a 25.8% stake in Nan Jing Kang Chuan Ji Pharmatech Co., Ltd. from Yin Laisheng for CNY 40 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥69.15

Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.14 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.04 in 1Q 2020)

New 90-day low: CN¥30.48

Investor sentiment deteriorated over the past week

New 90-day high: CN¥38.24

New 90-day high: CN¥35.97

New 90-day low: CN¥29.09

Third quarter earnings released

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q3, 2020 Results on Oct 22, 2020

Zhejiang Jiuzhou Pharmaceutical Co., Ltd announced that it expects to receive CNY 1 billion in funding

Price target raised to CN¥22.95

First half earnings released

Earnings released

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven